Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases
Abstract Background This study aims to assess the sustained immunological response to the SARS-CoV-2 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIRD) undergoing different treatment regimens. Methods We conducted a prospective observational study involving 157 AIRD patients...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-023-01620-7 |
| _version_ | 1797363515890073600 |
|---|---|
| author | Silvia Garcia-Cirera Joan Calvet Juan Francisco Delgado de la Poza Antoni Berenguer-Llergo Cristóbal Orellana Menna Rusiñol Maria Llop Marta Arévalo Alba Garcia-Pinilla Ester Costa Cristina Aymerich Rafael Gómez Anna Carreras Jordi Gratacós |
| author_facet | Silvia Garcia-Cirera Joan Calvet Juan Francisco Delgado de la Poza Antoni Berenguer-Llergo Cristóbal Orellana Menna Rusiñol Maria Llop Marta Arévalo Alba Garcia-Pinilla Ester Costa Cristina Aymerich Rafael Gómez Anna Carreras Jordi Gratacós |
| author_sort | Silvia Garcia-Cirera |
| collection | DOAJ |
| description | Abstract Background This study aims to assess the sustained immunological response to the SARS-CoV-2 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIRD) undergoing different treatment regimens. Methods We conducted a prospective observational study involving 157 AIRD patients without prior COVID-19 infection. Treatment regimens included non-treatment or glucocorticoid-only (not-treated/GCs), non-biological drugs, biological therapy, and JAK inhibitors. All participants completed the two-dose vaccine schedule, and 110 of them received an additional booster dose. Serum samples were collected approximately 3–6 months after the second and third vaccine doses to measure antibodies against the Spike protein (antiS-AB) and neutralizing antibodies (nAB) targeting six SARS-CoV-2 variants. Results Following the third dose, all patients exhibited a significant increase in antiS-AB (FC = 15, p < 0.0001). Patients under biological therapy had lower titres compared to the non-biological (66% decrease, p = 0.038) and the not-treated/GCs group (62% decrease, p = 0.0132), with the latter persisting after the booster dose (86% decrease, p = 0.0027). GC use was associated with lower antiS-AB levels in the biological group (87% decrease, p = 0.0124), although not statistically significant after confounders adjustment. nABs showed the highest positivity rates for the wild-type strain before (50%) and after the booster dose (93%), while the Omicron variant exhibited the lowest rates (11% and 55%, respectively). All variants demonstrated similar positivity patterns and good concordance with antiS-AB (AUCs from 0.896 to 0.997). Conclusions The SARS-CoV-2 vaccine booster strategy effectively elicited a sustained antibody immune response in AIRD patients. However, patients under biological therapies exhibited a reduced response to the booster dose, particularly when combined with GCs. |
| first_indexed | 2024-03-08T16:22:27Z |
| format | Article |
| id | doaj.art-813285b889c745a4b114c694f81db040 |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-03-08T16:22:27Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-813285b889c745a4b114c694f81db0402024-01-07T12:17:34ZengBMCEuropean Journal of Medical Research2047-783X2024-01-0129111310.1186/s40001-023-01620-7Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseasesSilvia Garcia-Cirera0Joan Calvet1Juan Francisco Delgado de la Poza2Antoni Berenguer-Llergo3Cristóbal Orellana4Menna Rusiñol5Maria Llop6Marta Arévalo7Alba Garcia-Pinilla8Ester Costa9Cristina Aymerich10Rafael Gómez11Anna Carreras12Jordi Gratacós13Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Immunology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Biostatistics and Bioinformatics at Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Rheumatology Department, Parc Taulí Hospital Universitari. Institut d’Investigació I Innovació Parc Taulí (I3PT-CERCA)Abstract Background This study aims to assess the sustained immunological response to the SARS-CoV-2 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIRD) undergoing different treatment regimens. Methods We conducted a prospective observational study involving 157 AIRD patients without prior COVID-19 infection. Treatment regimens included non-treatment or glucocorticoid-only (not-treated/GCs), non-biological drugs, biological therapy, and JAK inhibitors. All participants completed the two-dose vaccine schedule, and 110 of them received an additional booster dose. Serum samples were collected approximately 3–6 months after the second and third vaccine doses to measure antibodies against the Spike protein (antiS-AB) and neutralizing antibodies (nAB) targeting six SARS-CoV-2 variants. Results Following the third dose, all patients exhibited a significant increase in antiS-AB (FC = 15, p < 0.0001). Patients under biological therapy had lower titres compared to the non-biological (66% decrease, p = 0.038) and the not-treated/GCs group (62% decrease, p = 0.0132), with the latter persisting after the booster dose (86% decrease, p = 0.0027). GC use was associated with lower antiS-AB levels in the biological group (87% decrease, p = 0.0124), although not statistically significant after confounders adjustment. nABs showed the highest positivity rates for the wild-type strain before (50%) and after the booster dose (93%), while the Omicron variant exhibited the lowest rates (11% and 55%, respectively). All variants demonstrated similar positivity patterns and good concordance with antiS-AB (AUCs from 0.896 to 0.997). Conclusions The SARS-CoV-2 vaccine booster strategy effectively elicited a sustained antibody immune response in AIRD patients. However, patients under biological therapies exhibited a reduced response to the booster dose, particularly when combined with GCs.https://doi.org/10.1186/s40001-023-01620-7Autoimmune diseaseImmune responseCOVID19Neutralizing antibodies |
| spellingShingle | Silvia Garcia-Cirera Joan Calvet Juan Francisco Delgado de la Poza Antoni Berenguer-Llergo Cristóbal Orellana Menna Rusiñol Maria Llop Marta Arévalo Alba Garcia-Pinilla Ester Costa Cristina Aymerich Rafael Gómez Anna Carreras Jordi Gratacós Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases European Journal of Medical Research Autoimmune disease Immune response COVID19 Neutralizing antibodies |
| title | Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases |
| title_full | Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases |
| title_fullStr | Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases |
| title_full_unstemmed | Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases |
| title_short | Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases |
| title_sort | biological and glucocorticoids treatment impair the medium term immunogenicity to sars cov 2 mrna vaccines in autoimmune inflammatory rheumatic diseases |
| topic | Autoimmune disease Immune response COVID19 Neutralizing antibodies |
| url | https://doi.org/10.1186/s40001-023-01620-7 |
| work_keys_str_mv | AT silviagarciacirera biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT joancalvet biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT juanfranciscodelgadodelapoza biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT antoniberenguerllergo biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT cristobalorellana biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT mennarusinol biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT mariallop biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT martaarevalo biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT albagarciapinilla biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT estercosta biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT cristinaaymerich biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT rafaelgomez biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT annacarreras biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases AT jordigratacos biologicalandglucocorticoidstreatmentimpairthemediumtermimmunogenicitytosarscov2mrnavaccinesinautoimmuneinflammatoryrheumaticdiseases |